$VEEV

Schwenger Thomas D. sold $265K of VEEV

Schwenger Thomas D. (Pres. & Chief Customer Officer) sold 1,000 shares of VEEVA SYSTEMS INC (VEEV) at $265.20 ($0.27M total) on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schwenger Thomas D.
Published Sep 16, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VEEV
Neutral
high confidence
Mentioned
$VEEV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VEEVNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect Veeva's stock price or investor sentiment.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

Potential upcoming secondary offering or strategic shift not yet disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑14

Background

Form 4 filings disclose insider transactions to ensure market transparency.

Company-level read

Ticker impact

$VEEVNeutralHigh confidence
Context

Officer Thomas D. Schwenger sold 1,000 shares for $265,200 via a 10b5‑1 plan.

Expected impact

No material impact; price likely unchanged.

Evidence & confidence

Sale size is small relative to float and disclosed via Form 4, providing full transparency.

Market effects

None; Veeva operates in cloud‑based life‑sciences software, unaffected by this sale.

None; transaction is US‑based and limited in size.

None

Counterpoint

Even small insider sales can signal confidence issues; monitor for further disposals.

Key entities

  • Thomas D. Schwenger

    President & Chief Customer Officer of Veeva Systems

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VEEVMed

CFRA upgrades Veeva Systems (VEEV) to a Buy

CFRA upgraded Veeva Systems (VEEV) to Buy with a new price target. The consensus rating is Moderate Buy with an average target of $293.57. Veeva reported Q2 revenue of $927.96M and net profit of $273.43M, up from $789.08M and $200.31M last year. Insider sentiment is negative, with 63 insiders selling shares.

$VEEVHighAI 8/10

Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock.

Veeva Systems reported a 37% increase in net income to $273.4M and raised fiscal 2027 revenue guidance to $3.682B-$3.687B. Michael Burry trimmed his position but remains bullish, citing the company's intrinsic value and growth potential. Analysts expect Q3 EPS of $1.68 and have raised price targets, with a consensus 'Moderate Buy' rating and $292.52 average target.

$VEEVMedAI 8/10

Veeva Rises on Sales and Margin Gains, Guidance Raise

Veeva Systems (VEEV) reported Q2 fiscal 2027 revenue of $928M, up 18% YoY, with non-GAAP operating income of $415.9M. The company raised guidance to $3.687B in revenue and $9.21 in non-GAAP EPS. VEEV shares have risen 25% YTD, supported by strong institutional demand and robust fundamentals, including 3-year sales and EPS growth rates of 14.1% and 21.6%, respectively.

$VEEVHighAI 8/10

Watch Veeva, CrowdStrike, and More

Veeva Systems (VEEV) reported Q2 non-GAAP EPS of $2.35, revenue growth of 17.6% Y/Y to $928M, and raised its Q3 revenue forecast. CrowdStrike (CRWD) posted 25.6% Y/Y revenue growth to $1.47B. Dycom Industries (DY) fell 11.6% despite 45.6% Y/Y revenue growth to $2.01B due to segment pressures and higher costs.

$VEEVHighAI 8/10

Veeva (VEEV) Q2 2027 Earnings Call Transcript

Veeva Systems (VEEV) reported Q2 2027 revenues of $928.0 million, up 18% YoY, driven by growth in commercial and R&D segments. Subscription revenues rose 16% to $766.8 million. Non-GAAP operating income was $415.9 million, with a 44.8% margin. The company raised FY 2027 revenue guidance to $3.682B-$3.687B and EPS guidance to $9.21. Management highlighted strong adoption of Vault CRM and Data Cloud solutions, with 12 top 20 biopharmas committed to Vault CRM. Risks include the launch of the new Fa